利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

69 条记录 (耗时 0.028 秒)

    METHODS FOR TUMOR TREATMENT USING CD3XCD20 BISPECIFIC ANTIBODY
    7.
    发明公开
    METHODS FOR TUMOR TREATMENT USING CD3XCD20 BISPECIFIC ANTIBODY 审中-公开
    用CD3XCD20双特异性抗体治疗肿瘤的方法

    公开(公告)号：EP3221359A1

    公开(公告)日：2017-09-27

    申请号：EP15801637.8

    申请日：2015-11-17

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： SMITH, Eric ,  DAVIS, Samuel ,  VARGHESE, Bindu ,  KIRSHNER, Jessica R. ,  THURSTON, Gavin ,  LOWY, Israel ,  BROWNSTEIN, Carrie

    IPC分类号： C07K16/28 ,  G01N33/50 ,  A61K39/00

    摘要： The present invention relates to a method (dosage regimen) for administering a CD3×CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a CD3×CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3×CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims. A pharmaceutical package or kit comprising the first dose, the second dose, and any subsequent doses are also part of the present invention.

    摘要翻译： 本发明涉及用于向人类患者施用CD3xCD20双特异性抗体的方法（剂量方案），其包括（a）以特定剂量施用第一剂量的所述抗体; （b）在一段时间之后施用第二剂量的所述抗体，其中所述第二剂量超过所述第一剂量。 本发明的方法（以及同样的本发明的剂量方案）也适合于治疗人类患者的B细胞（CD20阳性）癌症或者用于改善和/或预防由周期性或持续给药介导的医学病症 的CD3 x CD20双特异性抗体给人类患者。 本发明还涉及CD3 x CD20双特异性抗体用于制备待用于如前述权利要求中任一项所定义的方法或治疗方案的药物组合物的用途。 包含第一剂量，第二剂量和任何后续剂量的药物包装或试剂盒也是本发明的一部分。

    HUMAN ANTIBODIES TO PD-1
    8.
    发明公开
    HUMAN ANTIBODIES TO PD-1 审中-公开
    MENSCHLICHEANTIKÖRPERGEGEN PD-1

    公开(公告)号：EP3097119A1

    公开(公告)日：2016-11-30

    申请号：EP15703187.3

    申请日：2015-01-23

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： PAPADOPOULOS, Nicholas, J. ,  MURPHY, Andrew, J. ,  THURSTON, Gavin ,  IOFFE, Ella ,  BUROVA, Elena

    IPC分类号： C07K16/28

    CPC分类号： A61N5/10 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death- 1 (PD-1 ) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T- cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.

    摘要翻译： 本发明提供结合T细胞共抑制剂程序性死亡-1（PD-1）蛋白的抗体及其使用方法。 在本发明的各种实施方案中，抗体是与PD-1结合的完全人抗体。 在某些实施方案中，本发明提供多特异性抗原结合分子，其包含结合PD-1的第一结合特异性和结合自身免疫组织抗原的第二结合特异性，另一种T细胞共抑制剂，Fc受体 ，或T细胞受体。 在一些实施方案中，本发明的抗体可用于抑制或中和PD-1活性，从而提供治疗诸如癌症或慢性病毒感染的疾病或病症的方法。 在其它实施方案中，抗体可用于增强或刺激PD-1活性，从而提供治疗例如自身免疫疾病或病症的方法。